Pre-Procedure Desmopressin Acetate to Reduce Bleeding in Renal Failure: Does It Really Work?

Radhakrishnan, Seetha; Chanchlani, Rahul; Connolly, Bairbre; Langlois, Valérie S.

doi:10.1159/000362455

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported in renal surgery (kidney biopsy), with certain subpopulations of patients (serum creatinine ≥1.8 mg/dl and GFR <15 ml/min/1.73 m 2 ) more likely to experience benefit with desmopressin (33,34).…”

Section: Results Of Literature Review and Discussion Of Findingssupporting

confidence: 79%

Potential clinical applications of current and future oral forms of desmopressin (Review)

Everaert,

Holm‑larsen,

Bou Kheir

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Desmopressin is a synthetic analogue of vasopressin and a selective vasopressin receptor 2 agonist. It was first synthesised in 1967 and utilised for its antidiuretic properties. It is also used in bleeding disorders to enhance clotting. Other potential uses of the drug have been reported. The present review aims to provide a broad overview of the literature on potential further uses of oral forms of desmopressin. Key therapeutic areas of interest were identified based on known physiological activities/targets of desmopressin or reports of an effect of desmopressin in the literature. The feasibility of adequate dosing with oral forms of the drug was also considered. Systematic literature searches were carried out using the silvi.ai software for the identified areas, and summaries of available papers were included in tables and discussed. The results of the searches showed that desmopressin has been investigated for its efficacy in a number of areas, including bleeding control, renal colic, the central nervous system and oncology. Evidence suggests that oral desmopressin may have the potential to be of clinical benefit for renal colic and bleeding control in particular. However, further research is needed to clarify its effect in these areas, including randomised controlled studies and studies specifically of oral formulations (and doses). Further research may also yield findings for cancer, cognition and overactive bladder. Contents 1. Introduction 2. Methods 3. Results of literature review and discussion of findings 4. Conclusion

show abstract

Section: Results Of Literature Review and Discussion Of Findingssupporting

confidence: 79%

Potential clinical applications of current and future oral forms of desmopressin (Review)

Everaert,

Holm‑larsen,

Bou Kheir

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…going antiplatelet treatment may benefit from desmopressin administration (6). Patients who are taking low-molecular-weight heparin can undergo the PBTI after abstaining from taking heparin for 12-24 hours.…”

Section: Biliary Accessmentioning

confidence: 99%

Diagnosis and Management of Complications from Percutaneous Biliary Tract Interventions

et al. 2017

View full text Add to dashboard Cite

Complications related to percutaneous biliary tract interventions (PBTIs) can range from access site discomfort to life-threatening vascular complications. These complications are relatively uncommon, and most of them are self-limiting. However, major complications for which an increased level of patient care and/or a prolonged hospital stay are required and that may lead to death-albeit rarely-can occur. Some of the most common complications related to PBTI include pain, infection, bile leakage, and catheter blockage. These conditions can be easily recognized by using the patient's clinical history and laboratory examination results. However, the more uncommon complications, such as life-threatening hemobilia, acute pancreatitis, and catheter and stent fractures, may have nonspecific clinical manifestations, and the underlying pathologic condition may be found only when it is being sought specifically. It is important that diagnostic and interventional radiologists be aware of the wide spectrum of PBTI-related complications, as early recognition and treatment may prevent catastrophic situations. In addition, knowledge of the different treatment options is essential for guidance in interventional radiology procedures such as transarterial control of hemobilia, imaging-guided direct percutaneous embolization of pseudoaneurysms, and percutaneous treatment of catheter- and stent-related complications such as fractures. The authors review a wide spectrum of complications associated with PBTI and the percutaneous management of these conditions. They also highlight valuable lessons learned from morbidity and mortality rounds at a high-volume tertiary care center. RSNA, 2017.

show abstract

“…Radhakrishnan et al [ 12 ] did not find a statistically significant reduction in bleeding for patients receiving preprocedural DDAVP in patients with GFR <60 mL/minute/1.73 m 2 in their study. However, in patients with an estimated glomerular filtration rate (eGFR) <15 mL/minute/1.73 m 2 , there was a trend toward a benefit for the role of DDAVP, but the numbers were small.…”

Section: Introductionmentioning

confidence: 69%

Desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with renal failure – Is it really beneficial?

et al. 2022

View full text Add to dashboard Cite

Introduction: The most common complication of percutaneous renal biopsy is bleeding, which can be seen in up to one-third of cases. The aim of this study was to evaluate the effect of prebiopsy administration of intranasal desmopressin acetate in reducing the incidence of biopsy-related bleeding complications in patients with significant renal dysfunction who underwent renal biopsy. Methods: This was a retrospective, observational study of percutaneous native renal biopsies performed at our center from July 2014 to June 2018. Bleeding complication rates of patients with renal failure (estimated glomerular filtration rate [eGFR] <30 mL/minute/1.73 m 2 ) who received desmopressin and those who did not receive desmopressin were compared. Results: Desmopressin administration before renal biopsy in patients with eGFR <30 mL/minute/1.73 m 2 was associated with a significant reduction of bleeding complications (major and minor together; P = 0.025) and no significant reduction in major complications ( P = 0.616) or intervention rates ( P = 0.251) when compared with a group that did not receive desmopressin. Conclusions: While prebiopsy intranasal desmopressin use was associated with a significant reduction of overall bleeding complications including major and minor complications, there was no reduction in the rate of other major complications and interventions.

show abstract

Pre-Procedure Desmopressin Acetate to Reduce Bleeding in Renal Failure: Does It Really Work?

Cited by 10 publications

References 14 publications

Potential clinical applications of current and future oral forms of desmopressin (Review)

Potential clinical applications of current and future oral forms of desmopressin (Review)

Diagnosis and Management of Complications from Percutaneous Biliary Tract Interventions

Desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with renal failure – Is it really beneficial?

Contact Info

Product

Resources

About